AskAdis is a new cutting-edge conversational chat interface developed by Springer Nature for the pharmaceutical drug development market using its AdisInsight, a market-leading drug development intelligence database with over half a million users annually.
Off-the-shelf LLMs (large language models) are often inaccurate, incomplete, or unreliable as they draw on all the content on which they have been trained to generate answers. Using Generative AI, AskAdis has been trained on only relevant already validated content, information, and data making results more accurate and reliable.
It has a natural language conversational chat interface that allows users to ask specific questions. This means users can refine the exact scope of the information they are looking for in the shortest possible time - an essential feature for the pharma industry where information can rapidly change, is highly complex, and can impact human life.
For over 180 years Springer Nature has been advancing discovery by providing the best possible service to the whole research community. We help researchers uncover new ideas, make sure all the research we publish is significant, robust, and stands up to objective scrutiny, that it reaches all relevant audiences in the best possible format, and can be discovered, accessed, used, re-used, and shared. We support librarians and institutions with innovations in technology and data and provide quality publishing support to societies.
As a research publisher, Springer Nature is home to trusted brands including Springer, Nature Portfolio, BMC, Palgrave Macmillan, and Scientific American.
Click here to read the original press release.
More News in this Theme
